Baseline MRI bone erosion predicts the subsequent radiographic progression in early rheumatoid arthritis patients who achieved sustained good clinical response

References

• Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.
   PubMed Web of Science ®Google Scholar
• Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75:16–22.
   PubMed Web of Science ®Google Scholar
• Quinn MA, Conaghan PG, O’Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27–35.
   PubMed Web of Science ®Google Scholar
• Durez P, Malghem J, Toukap AN, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007;56:3919–27.
   PubMed Web of Science ®Google Scholar
• Kosta PE, Voulgari PV, Zikou AK, Tsampoulas K, Drosos AA, Argyropoulou MI. Effect of very early treatment in rheumatoid arthritis on bone oedema and synovitis, using magnetic resonance imaging. Scand J Rheumatol. 2012;41:339–44.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Emery P, Ostergaard M, Keystone EC, Genovese MC, Hsia EC, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis. 2011;70:1968–74.
   PubMed Web of Science ®Google Scholar
• Kita J, Tamai M, Arima K, Kawashiri SY, Horai Y, Iwamoto N, et al. Significant improvement in MRI-proven bone edema is associated with protection from structural damage in very early RA patients managed using the tight control approach. Mod Rheumatol. 2013;23:254–9.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, DiCarlo J, et al. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Ann Rheum Dis. 2014;73:810–16.
   PubMed Web of Science ®Google Scholar
• Østergaard M, Jacobsson LTH, Schaufelberger C, Hansen MS, Bijlsma JWJ, Dudek A, et al. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Ann Rheum Dis. 2015;74:1156–63.
   PubMed Web of Science ®Google Scholar
• Døhn UM, Ejbjerg B, Boonen A, Hetland ML, Hansen MS, Knudsen LS, et al. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis. 2011;70:252–8.
   PubMed Web of Science ®Google Scholar
• Ostergaard M, Emery P, Conaghan PG, Fleischmann R, Hsia EC, Xu W, et al. Significant Improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naïve rheumatoid arthritis patients. Arthritis Rheum. 2011;63:3712–22.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Ostergaard M, Bowes MA, Wu C, Fuerst T, van der Heijde D, et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016;75:1024–33.
   PubMed Web of Science ®Google Scholar
• Colebatch A, Edwards C, Østergaard M, van der Heijde D, Valint P, D’Agostino MA, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72:804–14.
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Tamai M, Kita J, Michitsuji T, Shimizu T, Fukui S, et al. Magnetic resonance imaging bone edema at enrollment predicts rapid radiographic progression in patients with early RA: results from the Nagasaki University Early Arthritis Cohort. J Rheumatol. 2016;43:1278–84.
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573–86.
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404–13.
   PubMed Web of Science ®Google Scholar
• Gandjbakhch F, Haavardsholm EA, Conaghan PG, Ejbjerg B, Folts V, Brown AK, et al. Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a follow up MRI study of 254 patients in clinical remission or low disease activity. J Rheumatol. 2014;41:398–406.
   PubMed Web of Science ®Google Scholar
• Anandarajah A, Thiele R, Giampoli E, Monu J, Seo GS, Feng C, et al. Patients with rheumatoid arthritis in clinical remission manifest persistent joint inflammation on histology and imaging studies. J Rheumatol. 2014;41:2153–60.
   PubMed Web of Science ®Google Scholar
• Krabben A, Stomp W, van Nies JAB, Huizinga TWJ, van der Heijde D, Bloem JL, et al. MRI-detected subclinical joint inflammation is associated with radiographic progression. Ann Rheum Dis. 2014;73:2034–7.
   PubMed Web of Science ®Google Scholar
• Dale J, Stirling A, Zhang R, Purves D, Foley J, Sambrook M, et al. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann Rheum Dis. 2016;75:1043–50.
   PubMed Web of Science ®Google Scholar
• Tamai M, Kawakami A, Uetani M, Takao S, Arima K, Iwamoto N, et al. A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies. Arthritis Rheum. 2009;61:772–8.
   PubMed Web of Science ®Google Scholar
• Tamai M, Kita J, Nakashima Y, Suzuki T, Horai Y, Okada A, et al. Combination of MRI-detected bone marrow oedema with 2010 rheumatoid arthritis classification criteria improves the diagnostic probability of early rheumatoid arthritis. Ann Rheum Dis. 2014;73:2219–20.
   PubMed Web of Science ®Google Scholar
• Tamai M, Kawakami A, Uetani M, Takao S, Tanaka F, Fujikawa K, et al. Bone edema determined by magnetic resonance imaging reflects severe disease status in patients with early-stage rheumatoid arthritis. J Rheumatol. 2007;34:2154–7.
   PubMed Web of Science ®Google Scholar
• Tamai M, Kawakami A, Iwamoto N, Takao S, Tanaka F, Fujikawa K, et al. Comparative study of the detection of joint injury in early-stage rheumatoid arthritis by magnetic resonance imaging of the wrist and finger joints and physical examination. Arthritis Care Res. 2011;63:436–9.
   PubMed Web of Science ®Google Scholar
• Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of disease activity score (DAS)28- erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407–9.
   PubMed Web of Science ®Google Scholar
• Lassere M, McQueen F, Østergaard M, Conaghan P, Shnier R, Peterfy C, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Exercise 3: an international multicenter reliability study using the RA-MRI Score. J Rheumatol. 2003;30:1366–75.
   PubMed Web of Science ®Google Scholar
• Conaghan P, Lassere M, Østergaard M, Peterfy C, McQueen F, O’Connor P, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Exercise 4: an international multicenter longitudinal study using the RA-MRI Score. J Rheumatol. 2003;30:1376–9.
   PubMed Web of Science ®Google Scholar
• Genant HK, Peterfy CG, Westhovens R, Becker JC, Aranda R, Vratsanos G, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis. 2008;67:1084–9.
   PubMed Web of Science ®Google Scholar
• Baker JF, Conaghan P, Smolen JS, Aletaha D, Shults J, Emary P, et al. Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging–detected synovitis and radiographic progression. Arthritis Rheum. 2014;66:794–802.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Ejbjerg B, Hørslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis. 2009;68:384–90.
   PubMed Web of Science ®Google Scholar
• Haavardsholm EA, Bøyesen P, Østergaard M, Schildvold A, Kvien TK. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis. 2008;67:794–800.
   PubMed Web of Science ®Google Scholar
• Bøyesen P, Haavardsholm EA, Ostergaard M, van der Heijde D, Sesseng S, Kvien TK. MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis. 2011;70:428–33.
   PubMed Web of Science ®Google Scholar
• Baker JF, Ostergaard M, Emery P, Hsia EC, Lu J, Baker DG, et al. Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial. Ann Rheum Dis. 2014;73:1968–74.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuis WP, van Steenbergen HW, Stomp W, Stijnen T, Huizinga TWJ, Bloem JL, et al. The course of bone marrow edema in early undifferentiated arthritis and rheumatoid arthritis: a longitudinal magnetic resonance imaging study at bone level. Arthritis Rheumatol. 2016;68:1080–8.
   PubMed Web of Science ®Google Scholar
• Mangnus L, van Steenbergen HW, Reijnierse M, van der Helm-van Mil AHM. Magnetic resonance imaging–detected features of inflammation and erosions in symptom-free persons from the general population. Arthritis Rheumatol. 2016;68:2593–602.
   PubMed Web of Science ®Google Scholar